Vanguard Group’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,712,285
| Closed | -$108M | – | 4474 |
|
|
2024
Q1 | $108M | Buy |
2,712,285
+477,518
| +21% | +$14.1M | ﹤0.01% | 1821 |
|
|
2023
Q4 | $42.6M | Buy |
2,234,767
+759,888
| +52% | +$10.6M | ﹤0.01% | 2253 |
|
|
2023
Q3 | $16.9M | Buy |
1,474,879
+70,912
| +5% | +$873K | ﹤0.01% | 2613 |
|
|
2023
Q2 | $14.4M | Buy |
1,403,967
+34,258
| +3% | +$309K | ﹤0.01% | 2739 |
|
|
2023
Q1 | $10.6M | Buy |
1,369,709
+9,206
| +0.7% | +$73.3K | ﹤0.01% | 2909 |
|
|
2022
Q4 | $10M | Buy |
1,360,503
+237,703
| +21% | +$1.52M | ﹤0.01% | 2947 |
|
|
2022
Q3 | $8.08M | Buy |
1,122,800
+493,027
| +78% | +$4.06M | ﹤0.01% | 3060 |
|
|
2022
Q2 | $5.36M | Sell |
629,773
-77,825
| -11% | -$671K | ﹤0.01% | 3347 |
|
|
2022
Q1 | $6.35M | Buy |
707,598
+9,844
| +1% | +$85.1K | ﹤0.01% | 3404 |
|
|
2021
Q4 | $9.66M | Buy |
697,754
+117,276
| +20% | +$1.45M | ﹤0.01% | 3226 |
|
|
2021
Q3 | $6.19M | Buy |
580,478
+5,261
| +0.9% | +$48.5K | ﹤0.01% | 3521 |
|
|
2021
Q2 | $5.18M | Sell |
575,217
-126
| -0% | -$1.37K | ﹤0.01% | 3587 |
|
|
2021
Q1 | $6.1M | Buy |
575,343
+27,700
| +5% | +$345K | ﹤0.01% | 3424 |
|
|
2020
Q4 | $6.9M | Buy |
547,643
+230,752
| +73% | +$2.26M | ﹤0.01% | 3186 |
|
|
2020
Q3 | $2.79M | Buy |
316,891
+129,848
| +69% | +$1.19M | ﹤0.01% | 3388 |
|
|
2020
Q2 | $1.82M | Hold |
187,043
| – | – | ﹤0.01% | 3455 |
|
|
2020
Q1 | $538K | Hold |
187,043
| – | – | ﹤0.01% | 3657 |
|
|
2019
Q4 | $718K | Hold |
187,043
| – | – | ﹤0.01% | 3713 |
|
|
2019
Q3 | $733K | Sell |
187,043
-15,539
| -8% | -$66.7K | ﹤0.01% | 3726 |
|
|
2019
Q2 | $853K | Buy |
202,582
+81,800
| +68% | +$472K | ﹤0.01% | 3720 |
|
|
2019
Q1 | $829K | Buy |
120,782
+1,000
| +0.8% | +$6.23K | ﹤0.01% | 3675 |
|
|
2018
Q4 | $441K | Sell |
119,782
-108,052
| -47% | -$533K | ﹤0.01% | 3761 |
|
|
2018
Q3 | $1.44M | Buy |
227,834
+11,200
| +5% | +$78.3K | ﹤0.01% | 3624 |
|
|
2018
Q2 | $1.64M | Sell |
216,634
-5,387
| -2% | -$44.4K | ﹤0.01% | 3558 |
|
|
2018
Q1 | $1.78M | Buy |
222,021
+27,190
| +14% | +$269K | ﹤0.01% | 3501 |
|
|
2017
Q4 | $2.18M | Buy |
194,831
+42,504
| +28% | +$463K | ﹤0.01% | 3394 |
|
|
2017
Q3 | $1.77M | Buy |
152,327
+59,565
| +64% | +$557K | ﹤0.01% | 3438 |
|
|
2017
Q2 | $894K | Sell |
92,762
-10,045
| -10% | -$96.3K | ﹤0.01% | 3594 |
|
|
2017
Q1 | $1.2M | Buy |
102,807
+52,581
| +105% | +$533K | ﹤0.01% | 3534 |
|
|
2016
Q4 | $450K | Sell |
50,226
-17,695
| -26% | -$353K | ﹤0.01% | 3752 |
|
|
2016
Q3 | $2.21M | Buy |
67,921
+4,066
| +6% | +$99K | ﹤0.01% | 3349 |
|
|
2016
Q2 | $1.18M | Sell |
63,855
-3,037
| -5% | -$53.9K | ﹤0.01% | 3563 |
|
|
2016
Q1 | $1.12M | Buy |
66,892
+1,148
| +2% | +$23K | ﹤0.01% | 3566 |
|
|
2015
Q4 | $2.04M | Buy |
65,744
+15,774
| +32% | +$539K | ﹤0.01% | 3391 |
|
|
2015
Q3 | $2.59M | Buy |
49,970
+39,986
| +401% | +$2.63M | ﹤0.01% | 3255 |
|
|
2015
Q2 | $605K | Buy |
+9,984
| New | +$595K | ﹤0.01% | 3814 |
|
Vanguard Group's ALPN Position: Q2 2024 in Review
Vanguard Group sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 2,712,285 shares — an estimated $108M sold.
Vanguard Group first reported a position in ALPN in Q2 2015 and held it in 36 quarters. The position peaked at $108M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Vanguard Group reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Vanguard Group sold 2,712,285 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $108M.
- Vanguard Group first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 36 quarters.
- Vanguard Group's Alpine Immune Sciences Inc position peaked at $108M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.